May 1, 2020 -- Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.
The INO-4800 vaccine is currently being tested in the U.S. through a phase I clinical trial. If proved safe, it could advance to phase II and III clinical trials later this year. Meanwhile, Richter-Helm BioLogics will transfer and rapidly scale up production processes for the INO-4800 DNA plasmid using its VGXI manufacturing technology.
The manufacturing partnership, which aims to produce 1 million doses of INO-4800 in 2020, is partly funded through a $1.3 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI). Inovio also partners with Richter-Helm BioLogics for its DNA medicine candidate VGX-3100 for the potential treatment of HPV-related precancerous cervical dysplasia.